Research programme: interleukin-12 nanocapsules - TherapyX

Drug Profile

Research programme: interleukin-12 nanocapsules - TherapyX

Alternative Names: IL12-NanoCap®

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator TherapyX
  • Class Adjuvants; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Gonorrhoea

Most Recent Events

  • 27 Jul 2016 Preclinical trials in Gonorrhoea (Prevention) in USA (Vaginal)
  • 27 Jul 2016 Preclinical trials in Gonorrhoea in USA (Vaginal)
  • 27 Jul 2016 Preclinical trials in Cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top